MAYNE PHARMA Aktie

0,23 EUR 0,0000%

Zu Ihrem Onlinebroker

kaufen verkaufen

MAYNE PHARMA Aktienkurs : 25.05. ( 15 Min. verzögert)
0,227 € Letzter Kurs	0,00% Veränderung	0,227 € Vortag	0,227 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
0,227 - 0,227 Tag	0,398 - 0,207 52 Wochen	0 Tag	0 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

MAYNE PHARMA Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

11.05.

Mylan Raises 2012 Earnings Guidance

Last week, Mylan had announced that it has launched the first generic equivalent of Mayne Pharma's Doryx (150 mg), which is marketed by Warner Chilcott (WCRX - Snapshot Report). The US District Court for the District...
04.05.

Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2012

We and Mayne Pharma International Pty. Ltd., who licenses the DORYX patent to us, previously filed infringement lawsuits against Impax Laboratories, Inc. ("Impax") and...

01.05.

Hospira Reports First-Quarter 2012 Results

... in Cost of products sold resulting from acquisitions including Mayne Pharma Limited ("Mayne Pharma"), Javelin Pharmaceuticals, Inc. ("Javelin Pharma") and a generic injectable business by Hospira Healthcare India Private Limited ("Hospira...
01.05.

Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx

The antibiotic product is the generic version of Mayne Pharma's Doryx, marketed by Warner Chilcott in the USA, and is a tetracycline-class antimicrobial. The 150mg dosage had US sales of...
01.05.

Business news briefs: Heinz to keep specialty vinegar blend ketchup

... Nuvigil beginning June 2016, or earlier under certain circumstances. Separately, Mylan said it was beginning shipments of the generic version of Mayne Pharma's Doryx delayed-release antibiotic tablets after a favorable court decision in New Jersey.